Cargando…
Corrigendum to: Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205630/ https://www.ncbi.nlm.nih.gov/pubmed/33511983 http://dx.doi.org/10.1093/ibd/izab014 |
Ejemplares similares
-
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies
por: Sandborn, William J, et al.
Publicado: (2020) -
Corrections to “Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab”
por: Lenihan, D., et al.
Publicado: (2019) -
Corrigendum: Clostridium Difficile Infection Worsen Outcome of Hospitalized Patients with Inflammatory Bowel Disease
por: Zhang, Ting, et al.
Publicado: (2017) -
Corrigendum to: Gastrointestinal Surgery for Inflammatory Bowel Disease Persistently Lowers Microbiome and Metabolome Diversity
Publicado: (2021) -
Corrigendum to: Diagnostic Yield of Next-Generation Sequencing in Very Early-Onset Inflammatory Bowel Diseases: A Multicenter Study
por: Charbit-Henrion, Fabienne, et al.
Publicado: (2020)